Lexaria Bioscience (LEXX) Q2 2025 earnings summary

Executive summary

• DehydraTECH technology continues to be the core focus, with ongoing preclinical and clinical R&D targeting GLP-1/GIP drugs and CBD for diabetes, weight loss, and hypertension applications.

• Recent studies showed DehydraTECH-enhanced formulations reduced adverse events and matched or outperformed commercial comparators in animal and human trials.

• The company expanded its clinical pipeline, including new human and animal studies, and received regulatory approvals for further trials.

• Leadership changes included re-engagement of John Docherty as President and Chief Science Officer, and the formation of a Scientific Advisory Board.

Financial highlights

• Revenue for the six months ended February 28, 2025, was $357,923, up from $296,278 year-over-year, driven by increased IP licensing fees.

• Net loss attributable to shareholders was $5.4 million for the six months ended February 28, 2025, compared to $1.8 million for the same period last year.

• Operating expenses rose significantly, with R&D expenses increasing by $2.8 million year-over-year due to expanded clinical activities.

• Cash and cash equivalents stood at $6.5 million as of February 28, 2025.

Outlook and guidance

• Cash resources are expected to fund operations through Q4 2025, but substantial doubt exists regarding the ability to continue as a going concern beyond that without additional financing.

• Management anticipates continued increases in R&D spending and operating losses as clinical programs progress.